[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"plasma-multi-omics\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:plasma-multi-omics":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100584152",false,"NCT06885619","Prediction of LVAR and MACE in STEMI Though Plasma Multiomics Analysis","Prediction of Left Ventricular Adverse Remodeling and Major Adverse Cardiovascular Events in Patients With Acute ST-segment Elevation Myocardial Infarction Though Plasma Multiomics Analysis","Inclusion Criteria:\n\n1. Age ≥18 years and ≤80 years.\n2. Definite diagnosis of STEMI according to ESC\u002FACC guidelines:\n\n   * Chest pain lasting \\>30 minutes, and\n   * ST-segment elevation in at least two contiguous leads: ≥0.2 mV in leads V2-V3 (≥0.2 mV for men, ≥0.15 mV for women) or ≥0.1 mV in other leads, or new-onset left bundle branch block.\n3. Reperfusion therapy: Symptom onset to first medical contact ≤12 hours, and successful primary PCI (culprit vessel opened, post-procedure TIMI flow grade 3).\n4. First STEMI (no prior history of myocardial infarction).\n5. Left ventricular ejection fraction (by echocardiography within 24-48 hours after admission) ≥35%.\n6. Informed consent: Signed informed consent obtained, with willingness to undergo serial blood sampling and echocardiographic follow-up.\n\nExclusion Criteria:\n\n1. Non-atherosclerotic MI: coronary embolism, spasm, aortic dissection, myocarditis, Takotsubo.\n2. Severe comorbidities:\n\n   * Prior HF (NYHA ≥II);\n   * Severe CKD (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m² or dialysis);\n   * Severe liver disease (Child-Pugh B\u002FC);\n   * Active malignancy (life expectancy \\\u003C1 year);\n   * Severe hematologic disorders (thrombocytopenia, coagulopathy, active bleeding).\n3. Fibrinolysis-followed-by-PCI.\n4. Primary PCI complications:\n\n   * No-reflow\u002Fslow-flow (final TIMI \\\u003C2);\n   * Cardiogenic shock or mechanical complication within 7 days;\n   * In-hospital repeat revascularization.\n5. Inability to complete 6-month follow-up.\n6. Factors affecting blood sampling\u002Fexosome\u002Fimmune\u002Fproteome assays:\n\n   * Blood transfusion within 1 month;\n   * Known hemolytic disorder;\n   * Inadequate venous access.\n7. Pregnancy or lactation.","ALL","18 Years","80 Years",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","To identify plasma multi-omics biomarkers that predict left ventricular adverse remodeling (LVAR) and major adverse cardiovascular events (MACE) in patients with acute ST-segment elevation myocardial infarction, and to investigate the molecular pathways linked to LVAR and MACE.",[24,25,26,27,28],"Left Ventricular Remodeling","Plasma Multi-Omics","Acute ST-segment Elevation Myocardial Infarction","Immunomics","Major Adverse Cardiovascular Events","RECRUITING","2026-05-07",{"date":32,"type":33},"2026-05-12","ACTUAL",{"date":35,"type":33},"2025-05-01",{"date":37,"type":20},"2027-12-31",{"name":39,"class":40},"Beijing Anzhen Hospital","OTHER",""]